Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05201781 · ClinicalTrials.gov registry record · Phase 4
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
A Phase 4 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 295
- Enrollment target
- 20
- Study locations
NCT05201781: Recruiting Phase 4 study of Multiple Myeloma, sponsored by Janssen Research & Development.
NCT05201781 is a Phase 4 study of Multiple Myeloma that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 295 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05201781, a Phase 4 study of Multiple Myeloma, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 295 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Primary Outcome
Number of participants with new malignancies and recurrence of pre-existing malignancy will be reported.
Conditions Studied
Interventions
- DRUG Cilta-cel
Study Locations (20)
California
- City of Hope - Duarte
- University of California San Francisco - San Francisco
- Stanford University Medical Center - Stanford
Massachusetts
- Dana Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
- Massachusetts General Hospital - Boston
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
New Jersey
- Hackensack University Medical Center - Hackensack
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- Roswell Park Cancer Institute - Buffalo
- Mount Sinai Medical Center - New York
Arizona
- Mayo Clinic Cancer Center-Scottsdale - Phoenix
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2037-10-30 |
| Phase | Phase 4 |
What NCT05201781 shows while recruiting
NCT05201781 is an interventional study that assigns participants to a tested intervention. The registered 295 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Cilta-cel is the first listed.
NCT05201781 names 20 study sites across 13 states, led by California, Massachusetts, Illinois.
Frequently Asked Questions
What is clinical trial NCT05201781 about?
NCT05201781 is a clinical study titled "A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel". The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
What is the current status of trial NCT05201781?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 295 participants. The study started on 2022-03-09. Estimated completion is 2037-10-30.
What conditions does trial NCT05201781 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05201781?
The interventions under investigation include: Cilta-cel (DRUG).
Who is sponsoring clinical trial NCT05201781?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05201781 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05201781's enrollment target sits among peer trials
295 80th of 438 higher than 359 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
RECRUITING · Phase 4
-
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
RECRUITING · Phase 4
-
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
ACTIVE NOT RECRUITING · Phase 4
-
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
COMPLETED · Phase 4
-
Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
COMPLETED · Phase 4
-
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06004245 · 295 participants · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- NCT06494111 · 295 participants · Phase 2
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
- NCT07020221 · 295 participants · Phase 1
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- NCT05563792 · 296 participants · NA
Options for Pain Management Using Nonpharmacological Strategies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI